Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein

EMBO Molecular Medicine

Volumn 6, Issue 11, 2014, Pages 1436-1454

  Schepens, Bert ^a,b   Sedeyn, Koen ^a,b   Vande Ginste, Liesbeth ^a,b   De Baets, Sarah ^a,b   Schotsaert, Michael ^a,b   Roose, Kenny ^a,b   Houspie, Lieselot ^c   Van Ranst, Marc ^c   Gilbert, Brian ^d   van Rooijen, Nico ^e   Fiers, Walter ^a,b   Piedra, Pedro ^d   Saelens, Xavier ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Alveolar macrophages; Fc receptor; Human respiratory syncytial virus; Small hydrophobic protein; Vaccine

Indexed keywords

IMMUNOGLOBULIN G; PEPTIDE VACCINE; RESPIRATORY SYNCYTIAL VIRUS SMALL HYDROPHOBIC PROTEIN VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; ONCOPROTEIN; SMALL HYDROPHOBIC PROTEIN, VIRUS; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURFACE; CONTROLLED STUDY; COTTON RAT; FEMALE; HUMAN; HUMORAL IMMUNITY; HYDROPHOBICITY; IMMUNE RESPONSE; LUNG ALVEOLUS MACROPHAGE; MOUSE; NONHUMAN; RAT; RESPIRATORY SYNCYTIAL VIRUS INFECTION; T LYMPHOCYTE; VACCINATION; VIRUS REPLICATION; WEIGHT REDUCTION; ADOPTIVE TRANSFER; ADULT; AGED; ANIMAL; BAGG ALBINO MOUSE; BLOOD; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; LEUKAPHERESIS; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SIGMODONTINAE;

ADOPTIVE TRANSFER; ADULT; AGED; ANIMALS; ANTIBODIES, VIRAL; FEMALE; HUMANS; INFANT; LEUKOCYTE REDUCTION PROCEDURES; MACROPHAGES, ALVEOLAR; MALE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RETROVIRIDAE PROTEINS, ONCOGENIC; SIGMODONTINAE;

EID: 84910631735     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201404005     Document Type: Article

References (82)

1. Akerlind-Stopner B, Hu A, Mufson MA, Utter G, Norrby E (1993) Antibody responses of children to the C-terminal peptide of the SH protein of respiratory syncytial virus and the immunological characterization of this protein. J Med Virol 40: 112-120
2. Andreakos E (2012) Asthma exacerbations: a molecular dichotomy between antiviral and pro-inflammatory responses revealed. EMBO Mol Med 4: 1231-1233
3. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, Bont L (2013) Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 368: 1791-1799
4. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM et al (2012) Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 86: 11521-11532
5. Boukhvalova MS, Prince GA, Blanco JC (2009) The cotton rat model of respiratory viral infections. Biologicals 37: 152-159
6. Brandenburg AH, Groen J, van Steensel-Moll HA, Claas EC, Rothbarth PH, Neijens HJ, Osterhaus AD (1997) Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J Med Virol 52: 97-104
7. Bruhns P (2012) Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119: 5640-5649
8. Bukreyev A, Whitehead SS, Murphy BR, Collins PL (1997) Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J Virol 71: 8973-8982
9. Bukreyev A, Yang L, Fricke J, Cheng L, Ward JM, Murphy BR, Collins PL (2008) The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol 82: 12191-12204
10. Byrd LG, Prince GA (1997) Animal models of respiratory syncytial virus infection. Clin Infect Dis 25: 1363-1368
11. Carter SD, Dent KC, Atkins E, Foster TL, Verow M, Gorny P, Harris M, Hiscox JA, Ranson NA, Griffin S et al (2010) Direct visualization of the small hydrophobic protein of human respiratory syncytial virus reveals the structural basis for membrane permeability. FEBS Lett 584: 2786-2790
12. Chen MD, Vazquez M, Buonocore L, Kahn JS (2000) Conservation of the respiratory syncytial virus SH gene. J Infect Dis 182: 1228-1233
13. Cherrie AH, Anderson K, Wertz GW, Openshaw PJ (1992) Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. J Virol 66: 2102-2110
14. Collins PL, Graham BS (2008) Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 82: 2040-2055
15. Collins PL, Olmsted RA, Johnson PR (1990) The small hydrophobic protein of human respiratory syncytial virus: comparison between antigenic subgroups A and B. J Gen Virol 71(Pt 7): 1571-1576
16. Connors M, Collins PL, Firestone CY, Murphy BR (1991) Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol 65: 1634-1637
17. Corti D, Lanzavecchia A (2013) Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31: 705-742
18. De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W (2005) Universal influenza A vaccine: optimization of M2-based constructs. Virology 337: 149-161
19. DeVincenzo JP, El Saleeby CM, Bush AJ (2005) Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis 191: 1861-1868
20. Dilillo DJ, Tan GS, Palese P, Ravetch JV (2014) Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 20: 143-151
21. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, Van Rooijen N, Verbeek S, Fiers W, Saelens X (2011) Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 186: 1022-1031
22. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE (2005) Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352: 1749-1759
23. Falsey AR, Walsh EE (1992) Humoral immunity to respiratory syncytial virus infection in the elderly. J Med Virol 36: 39-43
24. Falsey AR, Walsh EE, Looney RJ, Kolassa JE, Formica MA, Criddle MC, Hall WJ (1999) Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults. J Med Virol 59: 221-226
25. Friedewald WT, Forsyth BR, Smith CB, Gharpure MA, Chanock RM (1968) Low-temperature-grown RS virus in adult volunteers. JAMA 204: 690-694
26. Gan SW, Tan E, Lin X, Yu D, Wang J, Tan GM, Vararattanavech A, Yeo CY, Soon CH, Soong TW et al (2012) The small hydrophobic protein of the human respiratory syncytial virus forms pentameric ion channels. J Biol Chem 287: 24671-24689
27. Glezen WP, Taber LH, Frank AL, Kasel JA (1986) Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140: 543-546
28. Graham BS (2011) Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 239: 149-166
29. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN (2014) The function of Fcgamma receptors in dendritic cells and macrophages. Nat Rev Immunol 14: 94-108
30. Hall CB, Long CE, Schnabel KC (2001) Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis 33: 792-796
31. Hall CB, Walsh EE, Long CE, Schnabel KC (1991) Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163: 693-698
32. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R et al (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286
33. Hazenbos WL, Gessner JE, Hofhuis FM, Kuipers H, Meyer D, Heijnen IA, Schmidt RE, Sandor M, Capel PJ, Daeron M et al (1996) Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity 5: 181-188
34. Henderson FW, Collier AM, Clyde WA Jr, Denny FW (1979) Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 300: 530-534
35. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW et al (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449: 101-104
36. Hogarth PM, Pietersz GA (2012) Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov 11: 311-331
37. Hussell T, Openshaw PJ (1998) Intracellular IFN-gamma expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection. J Gen Virol 79(Pt 11): 2593-2601
38. IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102: 531-537
39. Jegaskanda S, Weinfurter JT, Friedrich TC, Kent SJ (2013) Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J Virol 87: 5512-5522
40. Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M (2011) Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 10: 101-111
41. Klezovich-Benard M, Corre JP, Jusforgues-Saklani H, Fiole D, Burjek N, Tournier JN, Goossens PL (2012) Mechanisms of NK cell-macrophage Bacillus anthracis crosstalk: a balance between stimulation by spores and differential disruption by toxins. PLoS Pathog 8: e1002481
42. Kumaria R, Iyer LR, Hibberd ML, Simoes EA, Sugrue RJ (2011) Whole genome characterization of non-tissue culture adapted HRSV strains in severely infected children. Virol J 8: 372
43. Lapaque N, Walzer T, Meresse S, Vivier E, Trowsdale J (2009) Interactions between human NK cells and macrophages in response to Salmonella infection. J Immunol 182: 4339-4348
44. Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, Kozink DM, Hwang KK, Chen X, Tsao CY et al (2013) Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38: 176-186
45. Lima HN, Botosso VF, Oliveira DB, Campos AC, Leal AL, Silva TS, Bosso PA, Moraes CT, Filho CG, Vieira SE et al (2012) Molecular epidemiology of the SH (small hydrophobic) gene of human respiratory syncytial virus (HRSV), over 2 consecutive years. Virus Res 163: 82-86
46. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I, Campbell H, Cibulskis R, Li M et al (2012) Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 379: 2151-2161
47. Luchsinger V, Piedra PA, Ruiz M, Zunino E, Martinez MA, Machado C, Fasce R, Ulloa MT, Fink MC, Lara P et al (2012) Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus. Clin Infect Dis 54: 905-912
48. Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J (2012) HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog 8: e1002739
49. Magro M, Andreu D, Gomez-Puertas P, Melero JA, Palomo C (2010) Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein. J Virol 84: 7970-7982
50. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T et al (2013) Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340: 1113-1117
51. Meyer D, Schiller C, Westermann J, Izui S, Hazenbos WL, Verbeek JS, Schmidt RE, Gessner JE (1998) FcgammaRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia. Blood 92: 3997-4002
52. Mills JT, Van Kirk JE, Wright PF, Chanock RM (1971) Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J Immunol 107: 123-130
53. Moore ML, Chi MH, Goleniewska K, Durbin JE, Peebles RS Jr (2008) Differential regulation of GM1 and asialo-GM1 expression by T cells and natural killer (NK) cells in respiratory syncytial virus infection. Viral Immunol 21: 327-339
54. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N et al (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375: 1545-1555
55. Nair H, Simoes EA, Rudan I, Gessner BD, Azziz-Baumgartner E, Zhang JS, Feikin DR, Mackenzie GA, Moisi JC, Roca A et al (2013) Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet 381: 1380-1390
56. Nedvetzki S, Sowinski S, Eagle RA, Harris J, Vely F, Pende D, Trowsdale J, Vivier E, Gordon S, Davis DM (2007) Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood 109: 3776-3785
57. Nicholas JA, Levely ME, Mitchell MA, Smith CW (1989) A 16-amino acid peptide of respiratory syncytial virus 1A protein contains two overlapping T cell-stimulating sites distinguishable by class II MHC restriction elements. J Immunol 143: 2790-2796
58. Nimmerjahn F, Ravetch JV (2006) Fcgamma receptors: old friends and new family members. Immunity 24: 19-28
59. Olmsted RA, Collins PL (1989) The 1A protein of respiratory syncytial virus is an integral membrane protein present as multiple, structurally distinct species. J Virol 63: 2019-2029
60. Ordas I, Mould DR, Feagan BG, Sandborn WJ (2012) Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 91: 635-646
61. Piedra PA, Faden HS, Camussi G, Wong DT, Ogra PL (1989) Mechanism of lung injury in cotton rats immunized with formalin-inactivated respiratory syncytial virus. Vaccine 7: 34-38
62. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP (2003) Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 21: 3479-3482
63. Pribul PK, Harker J, Wang B, Wang H, Tregoning JS, Schwarze J, Openshaw PJ (2008) Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. J Virol 82: 4441-4448
64. Ramilo O, Lagos R, Saez-Llorens X, Suzich J, Wang CK, Jensen KM, Harris BS, Losonsky GA, Griffin MP (2014) Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J 33: 703-709
65. Rebuffo-Scheer C, Bose M, He J, Khaja S, Ulatowski M, Beck ET, Fan J, Kumar S, Nelson MI, Henrickson KJ (2011) Whole genome sequencing and evolutionary analysis of human respiratory syncytial virus A and B from Milwaukee, WI 1998-2010. PLoS One 6: e25468
66. Reed JL, Brewah YA, Delaney T, Welliver T, Burwell T, Benjamin E, Kuta E, Kozhich A, McKinney L, Suzich J et al (2008) Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis. J Infect Dis 198: 1783-1793
67. Remot A, Roux X, Dubuquoy C, Fix J, Bouet S, Moudjou M, Eleouet JF, Riffault S, Petit-Camurdan A (2012) Nucleoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: a candidate mucosal RSV vaccine. PLoS One 7: e37722
68. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E et al (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220
69. Rixon HW, Brown G, Aitken J, McDonald T, Graham S, Sugrue RJ (2004) The small hydrophobic (SH) protein accumulates within lipid-raft structures of the Golgi complex during respiratory syncytial virus infection. J Gen Virol 85: 1153-1165
70. Schepens B, Ibanez LI, De Baets S, Hultberg A, Bogaert P, De Bleser P, Vervalle F, Verrips T, Melero J, Vandevelde W et al (2011) Nanobodies(R) specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J Infect Dis 204: 1692-1701
71. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B (2000) Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 161: 1501-1507
72. Tan L, Coenjaerts FE, Houspie L, Viveen MC, van Bleek GM, Wiertz EJ, Martin DP, Lemey P (2013a) The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics. J Virol 87: 8213-8226
73. Tan L, Lemey P, Houspie L, Viveen MC, Jansen NJ, van Loon AM, Wiertz E, van Bleek GM, Martin DP, Coenjaerts FE (2013b) Genetic variability among complete human respiratory syncytial virus subgroup A genomes: bridging molecular evolutionary dynamics and epidemiology. PLoS One 7: e51439
74. Triantafilou K, Kar S, Vakakis E, Kotecha S, Triantafilou M (2013) Human respiratory syncytial virus viroporin SH: a viral recognition pathway used by the host to signal inflammasome activation. Thorax 68: 66-75
75. Van Rooijen N, Sanders A (1994) Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174: 83-93
76. Ventre K, Randolph AG (2007) Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev: CD000181
77. Wang W, Wang EQ, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84: 548-558
78. Welliver TP, Reed JL, Welliver RC Sr (2008) Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases. Pediatr Infect Dis J 27: S92-S96
79. White LJ, Waris M, Cane PA, Nokes DJ, Medley GF (2005) The transmission dynamics of groups A and B human respiratory syncytial virus (hRSV) in England & Wales and Finland: seasonality and cross-protection. Epidemiol Infect 133: 279-289
80. Whitehead SS, Hill MG, Firestone CY, St Claire M, Elkins WR, Murphy BR, Collins PL (1999) Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates. J Virol 73: 9773-9780
81. Wright PF, Gruber WC, Peters M, Reed G, Zhu Y, Robinson F, Coleman-Dockery S, Graham BS (2002) Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. J Infect Dis 185: 1011-1018
82. Yang DP, Zielinska E, Quiroz J, Madore D, Rappaport R (2007) Preparation of a respiratory syncytial virus human reference serum for use in the quantitation of neutralization antibody. Biologicals 35: 183-187